Zelavespib

DB12638InvestigationalSmall molecule

Zelavespib (PU-H71) has been used in trials studying the treatment of LYMPHOMA, Solid Tumors, Metastatic Solid Tumor, and Myeloproliferative Neoplasms (MPN).

Formula / weight: C₁₈H₂₁IN₆O₂S · 512.368 g/mol (avg)
Code names: PU-H-71

Resolves to

Compound

UNII06IVK87M04CAS873436-91-0ChEMBLCHEMBL200102PubChem9549213

Structure

InChIKeySUPVGFZUWFMATN-UHFFFAOYSA-NSMILESCC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC2=C(N)N=CN=C12

Targets

P08238HSP90AB1

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zelavespib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account